ATE470478T1 - An ovarialkrebs beteiligtes protein - Google Patents
An ovarialkrebs beteiligtes proteinInfo
- Publication number
- ATE470478T1 ATE470478T1 AT04769011T AT04769011T ATE470478T1 AT E470478 T1 ATE470478 T1 AT E470478T1 AT 04769011 T AT04769011 T AT 04769011T AT 04769011 T AT04769011 T AT 04769011T AT E470478 T1 ATE470478 T1 AT E470478T1
- Authority
- AT
- Austria
- Prior art keywords
- cdcp1
- protein involved
- ovarial cancer
- modulate
- expression
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102100035350 CUB domain-containing protein 1 Human genes 0.000 abstract 5
- 101000737742 Homo sapiens CUB domain-containing protein 1 Proteins 0.000 abstract 5
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0324656A GB0324656D0 (en) | 2003-10-22 | 2003-10-22 | A protein involved in ovarian cancer |
| PCT/GB2004/004502 WO2005042102A1 (en) | 2003-10-22 | 2004-10-22 | A protein involved in ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE470478T1 true ATE470478T1 (de) | 2010-06-15 |
Family
ID=29595617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04769011T ATE470478T1 (de) | 2003-10-22 | 2004-10-22 | An ovarialkrebs beteiligtes protein |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20070009543A1 (enExample) |
| EP (1) | EP1677875B1 (enExample) |
| JP (1) | JP4764344B2 (enExample) |
| AT (1) | ATE470478T1 (enExample) |
| AU (1) | AU2004285339B2 (enExample) |
| CA (1) | CA2541846A1 (enExample) |
| DE (1) | DE602004027647D1 (enExample) |
| ES (1) | ES2347249T3 (enExample) |
| GB (1) | GB0324656D0 (enExample) |
| PL (1) | PL1677875T3 (enExample) |
| WO (1) | WO2005042102A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| US20090274619A1 (en) * | 2006-01-26 | 2009-11-05 | George Coukos | Tumor vasculature markers and methods of use therof |
| US20130136689A1 (en) * | 2007-06-05 | 2013-05-30 | Christian Rohlff | Proteins |
| JP2010532484A (ja) * | 2007-06-29 | 2010-10-07 | コレロジック システムズ，インコーポレイテッド | 卵巣癌のための予測マーカー |
| TW201113037A (en) | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
| TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗ｃｄｃｐ１抗體 |
| EP2971259B8 (en) | 2013-03-13 | 2018-11-21 | NantEnergy, Inc. | Synergistic additives for electrochemical cells with electrodeposited fuel |
| WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
| WO2018112334A1 (en) | 2016-12-16 | 2018-06-21 | Bluefin Biomedicine, Inc. | Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof |
| US11424484B2 (en) | 2019-01-24 | 2022-08-23 | Octet Scientific, Inc. | Zinc battery electrolyte additive |
| EP4055058A4 (en) * | 2019-11-06 | 2023-12-06 | Commonwealth Scientific and Industrial Research Organisation | CUB DOMAIN-CONTAINING PROTEIN (CDCP1) BINDING PROTEINS |
| WO2021132427A1 (ja) | 2019-12-27 | 2021-07-01 | 株式会社カイオム・バイオサイエンス | 抗ｃｄｃｐ１抗体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5134799A (en) | 1998-07-30 | 2000-02-21 | Human Genome Sciences, Inc. | 98 human secreted proteins |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| US20020142003A1 (en) * | 2000-07-07 | 2002-10-03 | Norbert Schweifer | Tumor-associated antigen (B345) |
| WO2002004508A1 (de) | 2000-07-07 | 2002-01-17 | Boehringer Ingelheim International Gmbh | Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4 |
| US6783969B1 (en) | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
| BRPI0407680A (pt) | 2003-02-19 | 2006-03-01 | Novartis Ag | métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas |
-
2003
- 2003-10-22 GB GB0324656A patent/GB0324656D0/en not_active Ceased
-
2004
- 2004-10-22 DE DE200460027647 patent/DE602004027647D1/de not_active Expired - Lifetime
- 2004-10-22 PL PL04769011T patent/PL1677875T3/pl unknown
- 2004-10-22 US US10/575,311 patent/US20070009543A1/en not_active Abandoned
- 2004-10-22 AT AT04769011T patent/ATE470478T1/de active
- 2004-10-22 EP EP20040769011 patent/EP1677875B1/en not_active Revoked
- 2004-10-22 WO PCT/GB2004/004502 patent/WO2005042102A1/en not_active Ceased
- 2004-10-22 JP JP2006536183A patent/JP4764344B2/ja not_active Expired - Fee Related
- 2004-10-22 AU AU2004285339A patent/AU2004285339B2/en not_active Ceased
- 2004-10-22 ES ES04769011T patent/ES2347249T3/es not_active Expired - Lifetime
- 2004-10-22 CA CA 2541846 patent/CA2541846A1/en not_active Abandoned
-
2009
- 2009-10-14 US US12/587,870 patent/US8263071B2/en not_active Expired - Fee Related
-
2012
- 2012-08-03 US US13/566,011 patent/US9120860B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20130230524A1 (en) | 2013-09-05 |
| PL1677875T3 (pl) | 2010-11-30 |
| ES2347249T3 (es) | 2010-10-27 |
| US20070009543A1 (en) | 2007-01-11 |
| CA2541846A1 (en) | 2005-05-12 |
| GB0324656D0 (en) | 2003-11-26 |
| WO2005042102A1 (en) | 2005-05-12 |
| JP2007513873A (ja) | 2007-05-31 |
| DE602004027647D1 (de) | 2010-07-22 |
| AU2004285339B2 (en) | 2009-11-19 |
| EP1677875B1 (en) | 2010-06-09 |
| US20110059088A1 (en) | 2011-03-10 |
| US8263071B2 (en) | 2012-09-11 |
| US9120860B2 (en) | 2015-09-01 |
| EP1677875A1 (en) | 2006-07-12 |
| JP4764344B2 (ja) | 2011-08-31 |
| AU2004285339A1 (en) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| NO20083053L (no) | Humane monoklonale antistoffer mot O8E | |
| EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
| EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
| SG163554A1 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
| CY1126007T1 (el) | Προαγωγεις αποπτωσης | |
| CY1117124T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
| EA200801509A1 (ru) | Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7 | |
| EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
| ATE461220T1 (de) | Anti-egfr-antikörper | |
| MX358705B (es) | Agentes de union de esclerostina. | |
| DE60005953D1 (de) | Stapelbare statische mischelemente | |
| EA200600038A1 (ru) | Антитела, специфические в отношении склеростина, и способы увеличения минерализации кости | |
| CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
| EP1844077A4 (en) | DR5 ANTIBODIES AND THEIR USE | |
| UA108193C2 (uk) | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
| EA201170357A1 (ru) | Инженерные антитела к il-13: композиции, способы и применение | |
| CO2021011944A2 (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer | |
| EA201070636A1 (ru) | Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения | |
| DE60321041D1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
| ATE470478T1 (de) | An ovarialkrebs beteiligtes protein | |
| EA202191656A1 (ru) | Анти-il-36 антитела и способы их применения | |
| EA202092487A1 (ru) | Ферменты кинурениназы человека и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1677875 Country of ref document: EP |